LifeArc collaboration helps to advance a potential new cancer drug towards the clinic
Making our unique ULK inhibitors available as tools for the academic community has helped to reignite interest…
LifeArc works to bring new therapies and tests to patients. These case studies illustrate aspects of our work – to discuss how we can help please contact us.
Exploring new approaches to drug discovery
LifeArc’s scientists have been working on a fresh approach to drug discovery, using a parallel high-throughput application…
Developing the next generation of technology transfer specialists
Technology transfer is a highly trained and multidisciplinary scientific endeavour, providing the crucial link between academic research…
Rising to the challenge of COVID-19
While the development of COVID-19 vaccines has garnered much attention, scientists have also been looking at repurposed…
Collaboration leads to promising new approach for Alzheimer’s disease
A team from LifeArc and Göttingen University has developed a new approach to intervene in early-stage treatment…
How to kill a virus: LifeArc’s role in shaping the UK’s COVID-19 response
In 2020 the UK Government, supported by UK Research and Innovation and the National Institute for Health…
LifeArc supports MRC spin-out to Series A funding
Our technology transfer team has helped the Medical Research Council (MRC), a founder in PepGen, to advance…
LifeArc scientists play pivotal role in the search for a Covid-19 antibody therapy
While much attention in the race for treatments for Covid-19 has been on the development of new…
Virtual Reality technology for small molecular drug discovery
A project by an industrial placement student led to Virtual Reality becoming a powerful tool for drug…
Collaborating to conquer Alzheimer’s disease
LifeArc is supporting MRC scientists who want to see their discoveries go from bench to bedside Age-related…
Life, re-engineered: new milestone in the emerging field of synthetic genomics
When MRC researchers achieved a new milestone in the emerging field of synthetic genomics, LifeArc set this…
Modelling the human brain
Candidate drugs to treat the central nervous system could be screened with three-dimensional brain tissue grown in…
Joining the fight against tuberculosis
The World Health Organisation estimates around 10 million people across the world acquired tuberculosis (TB) in 2017.…
Alliance enables clinical trial of experimental treatment for epidermolysis bullosa
An experimental medicine to treat the rare inherited skin disorder epidermolysis bullosa (EB) is on track to…
Keytruda: a new generation of cancer treatment
In 2007, LifeArc entered a collaboration with Organon - ultimately acquired by Merck - to translate innovative…
Childhood cancers: smaller charities campaigning for new treatments
The genetic abnormalities that lead to cancer can occur at any age. Cancer is the major cause…
Jump starting research: SpringWorks Therapeutics – unlocking science
LifeArc's joint venture with Pfizer, Bain Capital and OrbiMed With a purpose of working in partnership with…
Fighting antibiotic resistance
A new approach to identifying antibacterial drug targets With the rapid increase in multi-drug-resistant (MDR) gram-negative bacteria,…
Cancer: LifeArc is working in partnership with Worldwide Cancer Research
We have worked in partnership with Worldwide Cancer Research (WCR) since 2011 to ensure that intellectual property…
Breast cancer: new treatment monitoring test avoids risks from biopsy
Through their shared dedication to patients, LifeArc and diagnostics company Biocartis are developing a ‘liquid biopsy’ test…
Renishaw Diagnostics: a test for antibiotic resistance
We collaborated with Renishaw Diagnostics Ltd. on a rapid diagnostic test for the detection of carbapenemase genes,…